Interview: Diane Gosselin, President and CEO, CQDM, Canada
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
MissionCQDM is a not-for-profit organization whose mission is to identify, fund and support joint research projects between the academic and private biopharmaceutical sectors. Projects funded by CQDM target the development of innovative tools and technologies that accelerate the drug discovery process.
Objectives
CQDM is dedicated first and last to the stimulation of research in the field of therapeutic medicine and in particular to the development of innovative tools facilitating the discovery of safer and more effective compounds. By promoting synergy between academic and industrial research and by creating an international exchange network, CQDM intends to expand Quebec’s leadership in biopharmaceutical research and open new research avenues that will have a strong impact on the industry. CQDM activities also benefit small biotechnology companies. Its unique team approach favours access to internationally renowned experts. By leading research efforts towards market expectations, CQDM fully plays its role in disseminating knowledge and creating economic value.
Québec Consortium for Drug Discovery (CQDM)
7140, Albert-Einstein, suite 100
Montreal (Québec) Canada
H4S 2C1
Tel.: 514 766-6661
Fax: 514 766-9613
email: cqdm@cqdm.org
http://www.cqdm.org/en/index.php
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders…
Industry veteran and CEO of JSS Medical research explains what he thinks is going wrong with clinical research in Canada today, how Canadian CROs are losing out at the hands…
The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients,…
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a company dedicated to bringing…
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes…
Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for…
A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and approval processes, removing duplication…
The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector…
See our Cookie Privacy Policy Here
